These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31977211)

  • 1. Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective.
    Wu C; Lee SL; Taylor C; Li J; Chan YM; Agarwal R; Temple R; Throckmorton D; Tyner K
    J Nat Prod; 2020 Feb; 83(2):552-562. PubMed ID: 31977211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.
    Manning ML; Thompson MD; Saber H; Maher VE; Crich JZ; Leighton JK
    Regul Toxicol Pharmacol; 2020 Feb; 110():104511. PubMed ID: 31678263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory science: a special update from the United States Food and Drug Administration: Preclinical issues and status of investigation of botanical drug products in the United States.
    Wu KM; DeGeorge JG; Atrakchi A; Barry E; Bigger A; Chen C; Du T; Freed L; Geyer H; Goheer A; Jacobs A; Jean D; Rhee H; Osterberg R; Schmidt W; Farrelly JG
    Toxicol Lett; 2000 Jan; 111(3):199-202. PubMed ID: 10643863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current regulatory perspectives on genotoxicity testing for botanical drug product development in the U.S.A.
    Wu KM; Dou J; Ghantous H; Chen S; Bigger A; Birnkrant D
    Regul Toxicol Pharmacol; 2010 Feb; 56(1):1-3. PubMed ID: 19782117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.
    Lapteva L; Pariser AR
    J Investig Med; 2016 Feb; 64(2):376-82. PubMed ID: 26911627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory toxicology perspectives on the development of botanical drug products in the United States.
    Wu KM; Farrelly J; Birnkrant D; Chen S; Dou J; Atrakchi A; Bigger A; Chen C; Chen Z; Freed L; Ghantous H; Goheer A; Hausner E; Osterberg R; Rhee H; Zhang K
    Am J Ther; 2004; 11(3):213-7. PubMed ID: 15133537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Building a drug development database: challenges in reliable data availability.
    Audibert C; Romine M; Caze A; Daniel G; Leff J; McClellan M
    Drug Dev Ind Pharm; 2017 Jan; 43(1):74-78. PubMed ID: 27494335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Consideration about data management and biostatistics analysis from a FDA's botanical drug approval case].
    Tang JY; Huang FH; Zhu FP
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Nov; 29(11):1035-9. PubMed ID: 20329620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical and biological characterization and clinical evaluation of botanical dietary supplements: a phase I red clover extract as a model.
    Piersen CE; Booth NL; Sun Y; Liang W; Burdette JE; van Breemen RB; Geller SE; Gu C; Banuvar S; Shulman LP; Bolton JL; Farnsworth NR
    Curr Med Chem; 2004 Jun; 11(11):1361-74. PubMed ID: 15180571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example.
    Black LE; Bendele AM; Bendele RA; Zack PM; Hamilton M
    Toxicol Pathol; 1999; 27(1):22-6. PubMed ID: 10367668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.
    Senderowicz AM
    Clin Cancer Res; 2010 Mar; 16(6):1719-25. PubMed ID: 20215544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current regulatory toxicology perspectives on the development of herbal medicines to prescription drug products in the United States.
    Wu KM; Ghantous H; Birnkrant DB
    Food Chem Toxicol; 2008 Aug; 46(8):2606-10. PubMed ID: 18614266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specialty molecules from plants and in vitro cultures as new drugs: regulatory considerations from flask to patient.
    Dou J; Weathers P
    Plant Cell Tissue Organ Cult; 2022; 149(1-2):105-111. PubMed ID: 35345535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators.
    Holbein ME
    J Investig Med; 2009 Aug; 57(6):688-94. PubMed ID: 19602987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine INDs: review of clinical holds.
    Miller DL; Ross JJ
    Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggregation and analysis of secondary pharmacology data from investigational new drug submissions at the US Food and Drug Administration.
    Dodson A; Mi K; Russo DP; Scott C; Saulnier M; Snyder K; Racz R
    J Pharmacol Toxicol Methods; 2021; 111():107098. PubMed ID: 34229067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The new drug approvals of 1990, 1991, and 1992: trends in drug development.
    Kaitin KI; Manocchia M; Seibring M; Lasagna L
    J Clin Pharmacol; 1994 Feb; 34(2):120-7. PubMed ID: 8163711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.